Clinical Infectious Diseases最新文献_第3页

Oral Fosfomycin for Pyelonephritis: Time for Evidence Over Eminence-based Guidelines. 口服磷霉素治疗肾盂肾炎：循证指南的时间。

IF 8.3 1区医学

Clinical Infectious Diseases Pub Date : 2026-10-14 DOI: 10.1093/cid/ciag552

Brad Spellberg, Sathyavani Subbarao, Alejandro Díaz Díaz, Jean Regina, Alejandro Delgado, Scott A Cohen, Miguel Morante-Ruiz, Boris Jegorović, Isabelle Chiu, Javier Santiago Araujo, Ernesto Cruz, Henco Nel, Ezequiel Cordova, Bernardo Vidal Pimentel, Steven Y C Tong, Daniel T Anderson, Zachary Nelson, Niccolò Riccardi, Mariana B Caiado Ferreira, Kusha Davar, Sarah Freling, Devin Clark, Noah Wald-Dickler, Rachel Baden, Nitin Gupta, Tomas Panesso Gomez, Jacob Jarboe, Ihab Ahmed, Bryan P White, Julian Ventres, Kyle Smiley, Andrew F Shorr, Blain G Thayer, Jhongert Alza-Arcila, Alberto Enrico Maraolo, Zeynep Ergenc, Todd C Lee, Bander A Assiri, Jessica S Moore, Alasdair P S Munro, Danilo Buonsenso, Gloria M Aguirre-Garcia, Andrés Blanco-Di Matteo, Matthew C Phillips, João Paulo Caldas, Pascal Meyer-Sautter, Genevieve McKew, Bassam Ghanem

引用次数: 0

Drug plasmatic level determination in malaria late treatment failures supports CDC recommendation for extending the duration of artemether-lumefantrine treatment. 疟疾晚期治疗失败的血浆药物水平测定支持疾病预防控制中心关于延长蒿甲醚-氨苯曲明治疗时间的建议。

IF 8.3 1区医学

Clinical Infectious Diseases Pub Date : 2026-10-14 DOI: 10.1093/cid/ciag655

Emilie Javelle, Nadim Cassir, Karim Mané, Nicolas Taudon, Bruno Pradines, Océane Delandre

引用次数: 0

Oral Fosfomycin for Complicated Urinary Tract Infection Remains a Murky Issue. 口服磷霉素治疗复杂尿路感染仍是一个模糊的问题。

IF 8.3 1区医学

Clinical Infectious Diseases Pub Date : 2026-10-14 DOI: 10.1093/cid/ciag553

Barbara W Trautner, Nicolas W Cortes-Penfield, Kalpana Gupta, Elizabeth B Hirsch, Valéry Lavergne

引用次数: 0

Leaving With Medical Advice: Why Prescribing Antibiotics to People with Endocarditis Who Leave the Hospital Early Makes Sense. 带着医疗建议离开：为什么给提前出院的心内膜炎患者开抗生素是有意义的。

IF 8.3 1区医学

Clinical Infectious Diseases Pub Date : 2026-10-14 DOI: 10.1093/cid/ciag650

Jonathan H Ryder, Alysse Wurcel

引用次数: 0

Risk Factors and Therapeutic Consequences of Virologic Failure With Long-Acting Cabotegravir Plus Rilpivirine in the Dat'AIDS Cohort. 长效卡博特韦加利匹韦林治疗艾滋病患者病毒学失败的危险因素和治疗结果。

IF 8.3 1区医学

Clinical Infectious Diseases Pub Date : 2026-10-14 DOI: 10.1093/cid/ciag654

Colin Deschanvres, Laurent Hocqueloux, André Cabié, Céline Robert, Alain Makinson, Benjamin Lefèvre, David Chirio, Simon Sunder, Cécile Goujard, François Raffi, Véronique Joly, Clotilde Allavena

{"title":"Risk Factors and Therapeutic Consequences of Virologic Failure With Long-Acting Cabotegravir Plus Rilpivirine in the Dat'AIDS Cohort.","authors":"Colin Deschanvres, Laurent Hocqueloux, André Cabié, Céline Robert, Alain Makinson, Benjamin Lefèvre, David Chirio, Simon Sunder, Cécile Goujard, François Raffi, Véronique Joly, Clotilde Allavena","doi":"10.1093/cid/ciag654","DOIUrl":"https://doi.org/10.1093/cid/ciag654","url":null,"abstract":"Background: Long-acting cabotegravir plus rilpivirine (CAB + RPV LA) is highly effective as maintenance therapy in virologically suppressed people with HIV (PWH), but virologic failure (VF) may lead to resistance and compromise future antiretroviral options.Methods: We conducted a multicenter observational study within the French Dat'AIDS cohort, including HIV-1 virologically suppressed adults who switched to CAB + RPV LA between December 2021 and December 2023. VF was defined as two consecutive HIV-1 RNA >50 copies/mL or one >200 copies/mL. Remaining options were interpreted using ANRS and Stanford algorithms. Cox models identified factors associated with VF.Results: Among 2,196 participants followed for a median of 13 months, VF occurred in 42 individuals (1.9%) after a median of 103 days. Among 26 VF cases undergoing genotype, resistance emerged in 13 (50%), with susceptibility maintained more often for doravirine (ANRS 92%, Stanford 96%) than for dolutegravir/bictegravir (ANRS 58%, Stanford 65%). Resistance also emerged during low-level viremia or transient rebound with re-suppression (7/13 cases). In multivariable analysis, higher BMI (aHR 1.07; 95%CI 1.01-1.14), nadir CD4 < 200 cells/mm3 (aHR 2.44; 1.31-4.56), and prior suppression <12 months (aHR 2.39; 1.01-5.19) were independently associated with VF. Historical CAB and RPV RAMs also increased VF risk.Conclusions: CAB + RPV LA was associated with low incidence of VF and rare resistance emergence. When resistance occurred, it primarily compromised bictegravir/dolutegravir rather than doravirine. Low nadir CD4, shorter prior suppression, higher BMI, and historical CAB and/or RPV RAMs support individualized candidate selection and early resistance testing, even during low-level viremia.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Randomized Trial Comparing Minocycline-EDTA-Ethanol Lock to Standard-of-Care Antibiotic Lock for Management of Central Line–Associated Bloodstream Infection 比较二甲胺四环素- edta -乙醇锁药与标准护理抗生素锁药治疗中央静脉相关血流感染的随机试验

IF 11.8 1区医学

Clinical Infectious Diseases Pub Date : 2026-10-14 DOI: 10.1093/cid/ciag660

Anne-Marie Chaftari, Vinay Rathore, Ray Hachem, Toan T Huynh, Paul P Cook, Onix Cantres-Fonseca, Mayur Ramesh, Princy N Kumar, Mark E Rupp, Leonard A Mermel, Myron S Czuczman, Alan Lader, Issam I Raad

{"title":"Randomized Trial Comparing Minocycline-EDTA-Ethanol Lock to Standard-of-Care Antibiotic Lock for Management of Central Line–Associated Bloodstream Infection","authors":"Anne-Marie Chaftari, Vinay Rathore, Ray Hachem, Toan T Huynh, Paul P Cook, Onix Cantres-Fonseca, Mayur Ramesh, Princy N Kumar, Mark E Rupp, Leonard A Mermel, Myron S Czuczman, Alan Lader, Issam I Raad","doi":"10.1093/cid/ciag660","DOIUrl":"https://doi.org/10.1093/cid/ciag660","url":null,"abstract":"Background Central line–associated bloodstream infections (CLABSI) cause substantial morbidity and mortality. Management often requires removing the infected central venous catheter (CVC) and inserting a new one. Effective catheter-salvage strategies are needed. Methods An international, multicenter, prospective, randomized superiority trial at 34 centers in the United States, Puerto Rico, and India enrolled patients aged ≥12 years with a long-term central venous catheter (CVC) in place for ≥5 days and CLABSI. Participants were randomized 1:1 to receive systemic antibiotics plus minocycline-EDTA-ethanol lock therapy (MLT) or standard-of-care antibiotic lock therapy (SOC-ALT) for 7 to 14 days. The primary endpoint was median time to catheter failure, defined as clinical failure (death, infection-related catheter removal, worsening symptoms) or microbial failure (persistent/recurrent infection or new deep-seated infection attributable to the index CLABSI). Results From 2018-2024, 241 patients were randomized; 228 received lock therapy. Catheter retention was higher with MLT than SOC-ALT (57% vs 38%; P = 0.0025). Median time to catheter failure was longer with MLT in both intention-to-treat (not estimable vs 33 days, HR 0.53, P = 0.0006) and modified intention-to-treat populations (not estimable vs 35 days, HR 0.50, P = 0.0005). Clinical catheter failure (13% vs 28%; P = 0.006) and microbiological failure (5% vs 15%; P = 0.012) were lower with MLT. Adverse events, serious adverse events, and mortality were similar between groups, with no drug-related serious adverse events. Conclusions MLT was superior to SOC-ALT in salvaging long-term CVCs in CLABSI and was well tolerated, addressing an unmet need in CLABSI management.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"408 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibiotic Stewardship, Resistance, and Mortality in Vancomycin-Resistant Enterococcus: A Quasi-Experimental Study of Linezolid Restrictions 万古霉素耐药肠球菌的抗生素管理、耐药性和死亡率：利奈唑胺限制的准实验研究

IF 11.8 1区医学

Clinical Infectious Diseases Pub Date : 2026-10-13 DOI: 10.1093/cid/ciag656

Edward L Kong, David W Kubiak, Erica S Shenoy, Alyssa R Letourneau

{"title":"Antibiotic Stewardship, Resistance, and Mortality in Vancomycin-Resistant Enterococcus: A Quasi-Experimental Study of Linezolid Restrictions","authors":"Edward L Kong, David W Kubiak, Erica S Shenoy, Alyssa R Letourneau","doi":"10.1093/cid/ciag656","DOIUrl":"https://doi.org/10.1093/cid/ciag656","url":null,"abstract":"Background Antibiotic restriction policies are intended to curb resistance, but their effects on resistance, timely treatment, and patient outcomes remain uncertain. We evaluated linezolid restrictions and whether vancomycin-resistant Enterococcus (VRE) screening identifies patients most likely to benefit. Methods We conducted a quasi-experimental difference-in-differences study using electronic health record data from 521,493 admissions at 2 academic medical centers from 2008 through 2019. Hospital 1 introduced a formal prior-authorization pager system in 2011 and stricter linezolid-specific criteria with enhanced post-prescription review in 2014; Hospital 2 served as a control. Outcomes included linezolid use, linezolid-resistant Enterococcus isolates, in-hospital mortality overall and by VRE status, and stewardship request behavior. Results Linezolid was used in 2.3% of admissions; 1.2% of Enterococcus isolates were linezolid resistant. Restriction policies were associated with a 27% reduction in linezolid use (-0.9 percentage points; 95% confidence interval, -1.1 to -0.7; P &lt; .001) and a 41% reduction in resistance (-1.0 percentage points; 95% confidence interval, -1.6 to -0.4; P = .003). Overall mortality did not increase, but mortality among VRE-screen-positive patients increased by 4.7 percentage points (95% confidence interval, 1.9 to 7.5; P &lt; .001), with larger increases among those with bacteremia or sepsis. Approval rates declined first, followed by fewer linezolid requests. Conclusions Restriction policies can reduce antibiotic use and resistance but may benefit from screening-informed safeguards to preserve timely treatment for high-risk patients.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"293 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Cephalosporins Versus Non-cephalosporin Antibiotics for Perioperative Prophylaxis in Primary Arthroplasty: A Systematic Review and Meta-Analysis. 纠正：头孢菌素与非头孢菌素抗生素用于初级关节置换术围手术期预防：系统回顾和荟萃分析。

IF 8.3 1区医学

Clinical Infectious Diseases Pub Date : 2026-10-13 DOI: 10.1093/cid/ciag366

引用次数: 0

Low Baseline RPR Titers and Serological Response: Persistent Questions Among People with HIV. 低基线RPR滴度和血清学反应：HIV感染者的持续问题。

IF 8.3 1区医学

Clinical Infectious Diseases Pub Date : 2026-10-13 DOI: 10.1093/cid/ciag645

José L Casado, Alejandro Vallejo

引用次数: 0

Does Low Baseline RPR Reflect Treatment Failure or Serologic Response Dynamics in Syphilis Among People With HIV? 低基线RPR是否反映HIV感染者梅毒治疗失败或血清学反应动力学？

IF 8.3 1区医学